Latest Reimbursement News

Emyria Limited reports that approximately 67% of patients treated for PTSD remain in remission over 12 months post-treatment, highlighting the potential for lasting recovery and cost-effective care.

Pure Foods Tasmania has reported a profitable quarter with improved margins and strategic growth moves, including a new contract packing deal and the acquisition of premium ice cream brand Elato.

Iceni Gold Limited reported a busy December quarter focused on advancing diamond drilling at its 14 Mile Well and Welcome Creek projects in Western Australia, with assay results expected soon and a cash position of $1.53 million.

333D Ltd reports continued revenue growth in digital asset management and unveils a pioneering blockchain solution for MRI data storage, reinforcing its foothold in digital healthcare.

Tissue Repair’s December quarter update reveals a cautious path forward for its Phase 3 TR987 trial amid slow patient recruitment, while its TR Pro+ product line gains momentum through a new distributor partnership and upcoming product launches.

Adherium Limited has exceeded its 2025 shipment goals for its Hailie Smartinhaler devices, driven by rapid growth in remote patient monitoring activations and improved US Medicare reimbursement policies.

Hydrocarbon Dynamics Limited has entered voluntary suspension pending a major transaction announcement while continuing global trials of its Multi-Flow product. A new auditor appointment and board leadership change mark a period of strategic transition.

Globe Metals & Mining has secured A$8.67 million through private placements, eliminated all debt, and commenced construction at its fully permitted Kanyika Niobium Project in Malawi, marking a pivotal shift from feasibility to execution.

HeraMED has secured pivotal US commercial agreements and achieved a key Australian regulatory milestone, positioning itself for scalable growth in digital maternity care.

IperionX has completed commissioning of its titanium powder and component manufacturing facilities, setting the stage for a major production scale-up backed by US Department of War funding. The company is progressing commercial contracts and advancing its critical minerals project in Tennessee.

PainChek has achieved FDA regulatory clearance enabling its device to qualify for US Remote Therapeutic Monitoring reimbursement, positioning the company for significant growth in the expanding US healthcare market. The company also reports strong global licence growth and a solid pipeline across multiple regions.

PainChek has secured FDA De Novo clearance, enabling entry into the vast US healthcare market with a $3 billion Remote Therapeutic Monitoring opportunity. The company reports $5.6 million contracted ARR and a strong global footprint in aged care.